-
EP1824498
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP1824498
| EP1824498 - METHODS AND COMPOSITIONS FOR TREATING CELLULAR PROLIFERATIVE DISEASES [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 20.08.2010 Database last updated on 04.12.2024 | Most recent event Tooltip | 20.08.2010 | Application deemed to be withdrawn | published on 22.09.2010 [2010/38] | Applicant(s) | For all designated states Massachusetts Institute of Technology 77 Massachusetts Avenue Cambridge, MA 02139 / US | [N/P] |
| Former [2007/35] | For all designated states THE MASSACHUSETTS INSTITUTE OF TECHNOLOGY 77 Massachusetts Avenue Cambridge, MA 02139 / US | Inventor(s) | 01 /
YAFFE, Michael, B. 1 Chesbrough Road West Roxbury, MA 02132 / US | 02 /
MANKE, Isaac, A. 500 Memorial Drive, 355 Cambridge, MA 02139 / US | 03 /
REINHARDT, Hans, Christian 34 Essex Street Cambride, MA 02139 / US | 04 /
LIM, Daniel 520 Cambridge Street, Suite 2 Cambridge, MA 02141 / US | [2007/35] | Representative(s) | Lahrtz, Fritz Patentanwälte Isenbruck Bösl Hörschler PartG mbB Prinzregentenstraße 68 81675 München / DE | [N/P] |
| Former [2007/35] | Lahrtz, Fritz Isenbruck Bösl Hörschler Wichmann Huhn, Patentattorneys, Prinzregentenstrasse 68 81675 München / DE | Application number, filing date | 05851642.8 | 14.11.2005 | [2007/35] | WO2005US41294 | Priority number, date | US20040627352P | 12.11.2004 Original published format: US 627352 P | [2007/35] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2006053315 | Date: | 18.05.2006 | Language: | EN | [2006/20] | Type: | A2 Application without search report | No.: | EP1824498 | Date: | 29.08.2007 | Language: | EN | The application published by WIPO in one of the EPO official languages on 18.05.2006 takes the place of the publication of the European patent application. | [2007/35] | Search report(s) | International search report - published on: | US | 09.11.2006 | (Supplementary) European search report - dispatched on: | EP | 27.05.2009 | Classification | IPC: | A61K31/00, A61K31/713, A61K38/08, A61N5/00, C12N15/11, A61K45/06, A61K47/48, C12Q1/48, C07K7/06, A61P35/00 | [2009/24] | CPC: |
C07K7/08 (EP,US);
A61K31/00 (EP,US);
A61K31/522 (EP,US);
A61K31/7048 (EP,US);
A61K31/7072 (EP,US);
A61K31/713 (EP,US);
A61K41/00 (EP,US);
A61K45/06 (EP,US);
A61K47/645 (EP,US);
A61K47/6455 (EP,US);
A61P35/00 (EP);
A61P35/02 (EP);
A61P43/00 (EP);
C07K7/06 (EP,US);
C12N15/1137 (EP,US);
C12N9/1205 (EP,US);
C12Q1/485 (EP,US);
C12Y207/11001 (EP,US);
G01N33/573 (EP,US);
G01N33/57407 (EP,US);
A61K38/00 (EP,US);
C07K2299/00 (EP,US);
C12N2310/14 (EP,US);
G01N1/30 (EP,US);
| C-Set: |
A61K31/00, A61K2300/00 (EP,US);
A61K41/00, A61K2300/00 (US,EP) |
| Former IPC [2007/35] | A61K31/7088 | Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR [2007/35] | Extension states | AL | Not yet paid | BA | Not yet paid | HR | Not yet paid | MK | Not yet paid | YU | Not yet paid | Title | German: | VERFAHREN UND ZUSAMMENSETZUNGEN ZUR BEHANDLUNG PROLIFERATIVER ZELLKRANKHEITEN | [2007/35] | English: | METHODS AND COMPOSITIONS FOR TREATING CELLULAR PROLIFERATIVE DISEASES | [2007/35] | French: | METHODES ET COMPOSITIONS DE TRAITEMENT DE MALADIES PROLIFERATIVES CELLULAIRES | [2007/35] | Entry into regional phase | 12.06.2007 | National basic fee paid | 12.06.2007 | Search fee paid | 12.06.2007 | Designation fee(s) paid | 12.06.2007 | Examination fee paid | Examination procedure | 12.06.2007 | Amendment by applicant (claims and/or description) | 12.06.2007 | Examination requested [2007/35] | 16.09.2009 | Despatch of a communication from the examining division (Time limit: M06) | 27.03.2010 | Application deemed to be withdrawn, date of legal effect [2010/38] | 03.05.2010 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2010/38] | Fees paid | Renewal fee | 27.11.2007 | Renewal fee patent year 03 | 25.11.2008 | Renewal fee patent year 04 | 25.11.2009 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]US2004209897 (VERNIER WILLIAM F [US], et al) [A] 1,2,6,11 * column W *; | [PA] - MANKE ISAAC A ET AL, "MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation", MOLECULAR CELL, (20050107), vol. 17, no. 1, ISSN 1097-2765, pages 37 - 48, XP002525960 [PA] 1,2,6,11 * the whole document * DOI: https://dx.doi.org/10.1016/J.MOLCEL.2004.11.021 | [A] - HIROSE YUICHI ET AL, "The p38 mitogen-activated protein kinase pathway links the DNA mismatch repair system to the G2 checkpoint and to resistance to chemotherapeutic DNA-methylating agents.", MOLECULAR AND CELLULAR BIOLOGY, (200311), vol. 23, no. 22, ISSN 0270-7306, pages 8306 - 8315, XP002525961 [A] 1,2,6,11 * the whole document * DOI: https://dx.doi.org/10.1128/MCB.23.22.8306-8315.2003 | [PA] - KUROSU T ET AL, "p38 MAP kinase plays a role in G2 checkpoint activation and inhibits apoptosis of human B cell lymphoma cells treated with etoposide", APOPTOSIS ; AN INTERNATIONAL JOURNAL ON PROGRAMMED CELL DEATH, KLUWER ACADEMIC PUBLISHERS, BO, (20051001), vol. 10, no. 5, ISSN 1573-675X, pages 1111 - 1120, XP019204740 [PA] 1,2,6,11 * the whole document * DOI: https://dx.doi.org/10.1007/s10495-005-3372-z | [A] - HAN Q ET AL, "Rac1-MKK3-p38-MAPKAPK2 pathway promotes urokinase plasminogen activator mRNA stability in invasive breast cancer cells", JOURNAL OF BIOLOGICAL CHEMISTRY 20021213 AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY INC. US, (20021213), vol. 277, no. 50, pages 48379 - 48385, XP002525962 [A] 1,2,6,11 * the whole document * DOI: https://dx.doi.org/10.1074/JBC.M.2095542200 | [T] - REINHARDT H CHRISTIAN ET AL, "p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage", CANCER CELL, (200702), vol. 11, no. 2, ISSN 1535-6108, pages 175 - 189, XP002525963 [T] 1,2,6,11 * the whole document * DOI: https://dx.doi.org/10.1016/J,CCR.2006.11.024 | [A] - SHAO RONG-GUANG ET AL, "Abrogation of Chk1-mediated S/G2 checkpoint by UCN-01 enhances ara-C-induced cytotoxicity in human colon cancer cells", ACTA PHARMACOLOGICA SINICA, (200406), vol. 25, no. 6, ISSN 1671-4083, pages 756 - 762, XP002525964 [A] 1,2,6,11 * the whole document * | [A] - TSE ARCHIE N ET AL, "Potentiation of cytotoxicity of topoisomerase I poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe", CANCER RESEARCH, (20040915), vol. 64, no. 18, ISSN 0008-5472, pages 6635 - 6644, XP002525965 [A] 1,2,6,11 * the whole document * DOI: https://dx.doi.org/10.1158/0008-5472.CAN-04-0841 | International search | [Y]US6683172 (KOTLYAROV ALEXEY [DE], et al); | [Y]WO2004055019 (PHARMACIA CORP [US], et al); | [Y] - SPORTSMAN J.R. ET AL., "Fluorescence Polarization Assays in Signal Transduction Discovery", COMB. CHEM. HIGH THROUGHPUT SCREENING, (2003), vol. 6, pages 195 - 200, XP009061455 | [Y] - HAYEES K. ET AL., "Effect of Protein Kinase Inhibitors on Activity of Mammalian Small Heat-Shock Protein (HSP25) Kinase", BIOCHEM. PHARM., (1997), vol. 53, pages 1239 - 1247, XP008119459 DOI: https://dx.doi.org/10.1016/S0006-2952(96)00877-5 | [A] - CHENG J.C. ET AL., "RNA interference and human disease", MOL. GEN. METAB., (2003), vol. 80, pages 121 - 128, XP001157375 DOI: https://dx.doi.org/10.1016/j.ymgme.2003.08.011 | [Y] - HAN Q. ET AL., "RAc1-MKK3-p38/MAPKAPK2 Pathway Promotes Urokinase Plasminogen Activator mRNA Stability in Invasive Breast Cancer Cells", J. BIO. CHEM., (2002), vol. 277, no. 50, pages 48379 - 48385, XP002525962 DOI: https://dx.doi.org/10.1074/JBC.M.2095542200 | [Y] - HIROSE Y. ET AL., "Cooperative function of Chk1 and p38 pathways in activating G2 arrest following exposure to temozolomide", J. NEUROSURG., (2004), vol. 100, pages 1060 - 1065, XP009115843 DOI: https://dx.doi.org/10.3171/jns.2004.100.6.1060 | [Y] - MIKHAILOV A. ET AL., "Topoisomerase II and histone deacetylase inhibitors delay the G2/M transition by triggering the p38 MAPK checkpoint pathway", J. CELL BIO., (2004), vol. 166, no. 4, pages 517 - 526, XP008119460 DOI: https://dx.doi.org/10.1083/jcb.200405167 | [A] - CARRASSA L. ET AL., "Chk1, but not Chk2, is Involved in the Cellular Response to DNA Damaging Agents", CELL CYCLE, (2004), vol. 3, no. 9, pages 1177 - 1181, XP009115840 | [Y] - IGNATOVICH I.A. ET AL., "Complexes of Plasmid DNA with Basic Domain 47-57 of the HIV-1 Tat Protein Are Transferred to Mammalian Cells by Endocytosis-mediated Pathways", J. BIO. CHEM., (2003), vol. 278, no. 43, pages 42625 - 42636, XP002297599 DOI: https://dx.doi.org/10.1074/jbc.M301431200 | [Y] - SAALIK P. ET AL, "Protein Cargo Delivery Properties of Cell-Penetrating Peptides: A Comparative Study", BIOCONJ. CHEM., (2004), vol. 15, pages 1246 - 1253, XP008119461 DOI: https://dx.doi.org/10.1021/bc049938y | [A] - SAKLATVALA J., "The p38 MAP kinase pathway as a therapeutic target in inflammatory disease", CURR. OP. PHARM., (2004), vol. 4, pages 373 - 377, XP008119482 DOI: https://dx.doi.org/10.1016/j.coph.2004.03.009 |